Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA. Camblin AJ, et al. Among authors: askoxylakis v. Clin Cancer Res. 2018 Jun 15;24(12):2873-2885. doi: 10.1158/1078-0432.CCR-17-2262. Epub 2018 Mar 16. Clin Cancer Res. 2018. PMID: 29549161
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models.
Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC. Kamoun WS, et al. Among authors: askoxylakis v. Nat Biomed Eng. 2019 Apr;3(4):264-280. doi: 10.1038/s41551-019-0385-4. Epub 2019 Apr 5. Nat Biomed Eng. 2019. PMID: 30952988
Targeting EphA2 in Bladder Cancer Using a Novel Antibody-Directed Nanotherapeutic.
Kamoun W, Swindell E, Pien C, Luus L, Cain J, Pham M, Kandela I, Huang ZR, Tipparaju SK, Koshkaryev A, Askoxylakis V, Kirpotin DB, Bloom T, Mino-Kenudson M, Marks JD, Zalutskaya A, Bshara W, Morrison C, Drummond DC. Kamoun W, et al. Among authors: askoxylakis v. Pharmaceutics. 2020 Oct 20;12(10):996. doi: 10.3390/pharmaceutics12100996. Pharmaceutics. 2020. PMID: 33092175 Free PMC article.
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models.
Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ. Kamoun WS, et al. Among authors: askoxylakis v. Mol Cancer Ther. 2020 Jan;19(1):270-281. doi: 10.1158/1535-7163.MCT-19-0414. Epub 2019 Oct 9. Mol Cancer Ther. 2020. PMID: 31597714
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RK. Kodack DP, et al. Among authors: askoxylakis v. Sci Transl Med. 2017 May 24;9(391):eaal4682. doi: 10.1126/scitranslmed.aal4682. Sci Transl Med. 2017. PMID: 28539475 Free PMC article.
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment.
Askoxylakis V, Ferraro GB, Kodack DP, Badeaux M, Shankaraiah RC, Seano G, Kloepper J, Vardam T, Martin JD, Naxerova K, Bezwada D, Qi X, Selig MK, Brachtel E, Duda DG, Huang P, Fukumura D, Engelman JA, Jain RK. Askoxylakis V, et al. J Natl Cancer Inst. 2015 Nov 7;108(2):djv313. doi: 10.1093/jnci/djv313. Print 2016 Feb. J Natl Cancer Inst. 2015. PMID: 26547932 Free PMC article.
Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy.
Ager EI, Kozin SV, Kirkpatrick ND, Seano G, Kodack DP, Askoxylakis V, Huang Y, Goel S, Snuderl M, Muzikansky A, Finkelstein DM, Dransfield DT, Devy L, Boucher Y, Fukumura D, Jain RK. Ager EI, et al. Among authors: askoxylakis v. J Natl Cancer Inst. 2015 Feb 20;107(4):djv017. doi: 10.1093/jnci/djv017. Print 2015 Apr. J Natl Cancer Inst. 2015. PMID: 25710962 Free PMC article.
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival.
Kloepper J, Riedemann L, Amoozgar Z, Seano G, Susek K, Yu V, Dalvie N, Amelung RL, Datta M, Song JW, Askoxylakis V, Taylor JW, Lu-Emerson C, Batista A, Kirkpatrick ND, Jung K, Snuderl M, Muzikansky A, Stubenrauch KG, Krieter O, Wakimoto H, Xu L, Munn LL, Duda DG, Fukumura D, Batchelor TT, Jain RK. Kloepper J, et al. Among authors: askoxylakis v. Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4476-81. doi: 10.1073/pnas.1525360113. Epub 2016 Apr 4. Proc Natl Acad Sci U S A. 2016. PMID: 27044098 Free PMC article.
52 results